NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
LANOXIN PEDIATRIC (digoxin) by Pfizer is digoxin's actions are mediated through its effects on na-k atpase. First approved in 1954.
Drug data last refreshed Yesterday
Mechanism of Action
digoxin's actions are mediated through its effects on Na-K ATPase. This enzyme, the "sodium pump," is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting Na-K ATPase, digoxin causes increased availability…
Pharmacologic Class:
Cardiac Glycoside
Indications
Worked on LANOXIN PEDIATRIC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.